Cargando…
Hypothyroidism in Context: Where We’ve Been and Where We’re Going
Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822815/ https://www.ncbi.nlm.nih.gov/pubmed/31485975 http://dx.doi.org/10.1007/s12325-019-01080-8 |
_version_ | 1783464412861956096 |
---|---|
author | Chiovato, Luca Magri, Flavia Carlé, Allan |
author_facet | Chiovato, Luca Magri, Flavia Carlé, Allan |
author_sort | Chiovato, Luca |
collection | PubMed |
description | Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in areas of iodine sufficiency, Hashimoto’s disease (chronic autoimmune thyroiditis) is the most common cause of thyroid failure. Hypothyroidism is diagnosed biochemically, being overt primary hypothyroidism defined as serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range. Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities, while the consequences of untreated or under-treated hypothyroidism include cardiovascular disease and increased mortality. Levothyroxine has long been the main tool for treating hypothyroidism and is one of the world’s most widely prescribed medicines. In adults with overt hypothyroidism, levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve optimal TSH levels (0.4–4.0 mIU/L), according to the therapeutic target. We here summarise the history of levothyroxine and discuss future issues regarding the optimal treatment of hypothyroidism. Because nearly one-third of patients with treated hypothyroidism still exhibit symptoms, it is important that levothyroxine is used more appropriately to achieve maximum benefit for patients. In order to ensure this, further research should include more accurate assessments of the true prevalence of hypothyroidism in the community, optimisation of the levothyroxine substitution dose, proper duration of treatment, and identification of patients who may benefit from combination therapy with levothyroxine plus levotriiodothyronine. Funding: Merck. Plain Language Summary: Plain language summary available for this article. |
format | Online Article Text |
id | pubmed-6822815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-68228152019-11-06 Hypothyroidism in Context: Where We’ve Been and Where We’re Going Chiovato, Luca Magri, Flavia Carlé, Allan Adv Ther Review Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in areas of iodine sufficiency, Hashimoto’s disease (chronic autoimmune thyroiditis) is the most common cause of thyroid failure. Hypothyroidism is diagnosed biochemically, being overt primary hypothyroidism defined as serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range. Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities, while the consequences of untreated or under-treated hypothyroidism include cardiovascular disease and increased mortality. Levothyroxine has long been the main tool for treating hypothyroidism and is one of the world’s most widely prescribed medicines. In adults with overt hypothyroidism, levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve optimal TSH levels (0.4–4.0 mIU/L), according to the therapeutic target. We here summarise the history of levothyroxine and discuss future issues regarding the optimal treatment of hypothyroidism. Because nearly one-third of patients with treated hypothyroidism still exhibit symptoms, it is important that levothyroxine is used more appropriately to achieve maximum benefit for patients. In order to ensure this, further research should include more accurate assessments of the true prevalence of hypothyroidism in the community, optimisation of the levothyroxine substitution dose, proper duration of treatment, and identification of patients who may benefit from combination therapy with levothyroxine plus levotriiodothyronine. Funding: Merck. Plain Language Summary: Plain language summary available for this article. Springer Healthcare 2019-09-04 2019 /pmc/articles/PMC6822815/ /pubmed/31485975 http://dx.doi.org/10.1007/s12325-019-01080-8 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Chiovato, Luca Magri, Flavia Carlé, Allan Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title | Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title_full | Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title_fullStr | Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title_full_unstemmed | Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title_short | Hypothyroidism in Context: Where We’ve Been and Where We’re Going |
title_sort | hypothyroidism in context: where we’ve been and where we’re going |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822815/ https://www.ncbi.nlm.nih.gov/pubmed/31485975 http://dx.doi.org/10.1007/s12325-019-01080-8 |
work_keys_str_mv | AT chiovatoluca hypothyroidismincontextwherewevebeenandwhereweregoing AT magriflavia hypothyroidismincontextwherewevebeenandwhereweregoing AT carleallan hypothyroidismincontextwherewevebeenandwhereweregoing |